Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)

Allergan

Status: Completed

Conditions: Macular Edema; Retinal Vein Occlusion

Treatments: Drug: dexamethasone intravitreal implant 0.7 mg

Study type: Observational

Funder types: Industry

Identifiers

NCT01411696

GMA-320 (Other Identifier)

GMA-OZU-09-011

Details and patient eligibility

About

This is a retrospective data collection study to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular edema due to RVO. Following informed consent, there were no patient study visits. All data was collected via chart review.

Enrollment: 289 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Macular edema
• Received at least 2 OZURDEX® injections

Exclusion criteria

• Received OZURDEX® injections as part of a clinical study

Trial design

289 participants in 1 patient group

All Participants

Description:

Patients who received at least 2 injections of OZURDEX® (dexamethasone intravitreal implant) to treat Macular Edema.

Treatment:

Drug: dexamethasone intravitreal implant 0.7 mg